Alterola Biotech Financials

ABTI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2024 Currency USD FYE March

This page shows Alterola Biotech (ABTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Alterola Biotech passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.61x

For every $1 of reported earnings, Alterola Biotech generates $0.61 in operating cash flow (-$1.4M OCF vs -$2.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$2.4M

YoY-14.6%

Alterola Biotech reported -$2.4M in net income in fiscal year 2024. This represents a decrease of 14.6% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3K

YoY-70.1%

Alterola Biotech held $3K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

1.38B

YoY+71.3%

Alterola Biotech had 1.38B shares outstanding in fiscal year 2024. This represents an increase of 71.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$29K

YoY-84.2%

Alterola Biotech invested $29K in research and development in fiscal year 2024. This represents a decrease of 84.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ABTI Income Statement

Metric	FY24	FY23	FY21	FY19	FY18	FY17
Revenue	N/A	N/A	N/A	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$29K-84.2%	$182K	N/A	N/A	N/A	N/A
SG&A Expenses	$252K+272.1%	$68K+1254.4%	$5K+856.0%	$523+49.9%	$349+2.3%	$341
Operating Income	-$2.1M-3.7%	-$2.0M-556.8%	-$310K-19.8%	-$258K-110.9%	-$123K-149.4%	-$49K
Interest Expense	N/A	N/A	N/A	$249-97.6%	$11K-43.2%	$19K
Income Tax	N/A	N/A	$82K0.0%	$82K+360.8%	$18K-22.2%	$23K
Net Income	-$2.4M-14.6%	-$2.1M-569.2%	-$310K-19.6%	-$259K-128.8%	-$113K-67.2%	-$68K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$17K-11.3%	$19K	N/A	$3K	$0	$0	N/A	N/A
SG&A Expenses	$24K-44.7%	$43K	N/A	$24K+0.4%	$24K+275.8%	$6K	N/A	-$28K
Operating Income	-$477K+30.1%	-$683K	N/A	-$1.1M-800.4%	-$123K+79.0%	-$585K	N/A	-$541K
Interest Expense	$337K	N/A	N/A	N/A	$337K	N/A	N/A	N/A
Income Tax	$0	$0	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$799K-22.1%	-$655K	N/A	-$2.0M-1532.3%	-$123K+72.5%	-$447K	N/A	-$535K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00

ABTI Balance Sheet

Metric	FY24	FY23	FY21	FY19	FY18	FY17
Total Assets	$4K-100.0%	$12.0M+2320962.6%	$519-96.5%	$15K-70.9%	$51K+19567.4%	$258
Current Assets	$4K-92.1%	$46K+8823.9%	$519-96.5%	$15K-70.9%	$51K	N/A
Cash & Equivalents	$3K-70.1%	$9K+1612.9%	$519	$0	$0	$0
Inventory	$1K+1.9%	$990	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-41.7%	$2.3M+200.8%	$760K+249.3%	$217K+104.5%	$106K-63.9%	$295K
Current Liabilities	$1.3M-37.4%	$2.1M+180.4%	$760K+249.3%	$217K+151.8%	$86K-70.7%	$295K
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$20K	$0
Total Equity	-$1.3M-113.6%	$9.8M+1385.9%	-$759K-274.5%	-$203K-264.8%	-$56K+81.1%	-$295K
Retained Earnings	-$12.4M-23.6%	-$10.0M-569.7%	-$1.5M-54.4%	-$971K-125.7%	-$430K+25.7%	-$580K

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$1.4M+39.9%	$975K+26523.7%	$4K+2.1%	$4K-99.3%	$497K-96.1%	$12.7M+5.4%	$12.0M-1.3%	$12.2M
Current Assets	$1.1M+60.4%	$715K+19427.0%	$4K+2.1%	$4K-98.2%	$197K-14.7%	$231K+399.2%	$46K-75.9%	$192K
Cash & Equivalents	$83K-88.4%	$714K+26812.7%	$3K+3.1%	$3K-71.7%	$9K-75.1%	$37K+311.1%	$9K-30.6%	$13K
Inventory	$1K+5.7%	$1K+0.2%	$1K-0.6%	$1K+4.1%	$975-3.4%	$1K+1.9%	$990+2.4%	$967
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+2.1%	$2.3M+15.8%	$2.0M
Current Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+9.6%	$2.1M+16.9%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	$20K	N/A	N/A	N/A
Total Equity	-$2.1M-49.4%	-$1.4M-3.5%	-$1.3M+1.9%	-$1.4M+33.0%	-$2.0M-119.9%	$10.2M+4.1%	$9.8M-4.6%	$10.2M
Retained Earnings	-$13.7M-5.3%	-$13.0M-4.6%	-$12.4M+0.2%	-$12.4M-19.3%	-$10.4M-1.3%	-$10.3M-2.5%	-$10.0M-5.1%	-$9.6M

ABTI Cash Flow Statement

Metric	FY24	FY23	FY21	FY19	FY18	FY17
Operating Cash Flow	-$1.4M-10.7%	-$1.3M-2514.5%	-$50K	$0+100.0%	-$20K	$0
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$140K	$0	$0	$0	$0
Financing Cash Flow	$1.5M+22.5%	$1.2M+2298.1%	$50K	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$861K-315.4%	-$207K-181.5%	-$74K+93.7%	-$1.2M-131.3%	-$508K-263.6%	$311K+306.2%	-$151K+81.0%	-$793K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$60K	$0	N/A	N/A	$202K+221.0%	-$167K-37.2%	-$122K	N/A
Financing Cash Flow	$400K-56.7%	$923K+414.8%	$179K-85.2%	$1.2M+964.3%	$114K+396.0%	-$39K-136.5%	$106K-86.7%	$796K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0

ABTI Financial Ratios

Metric	FY24	FY23	FY21	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-21.2%	N/A	N/A	N/A	N/A
Return on Assets	-64820.6%-64803.4pp	-17.2%+59616.7pp	-59633.9%-57879.1pp	-1754.9%-1532.0pp	-222.8%+25991.1pp	-26214.0%
Current Ratio	0.00-0.0	0.02+0.0	0.00-0.1	0.07-0.5	0.59	N/A
Debt-to-Equity	-1.00-1.2	0.23+1.2	-1.00-1.0	0.00+0.4	-0.36-0.4	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-4.4%	N/A	-5.2%
Return on Assets	-58.6%+8.6pp	-67.1%	N/A	-56013.4%-55988.7pp	-24.8%-21.3pp	-3.5%	N/A	-4.4%
Current Ratio	0.32+0.0	0.29+0.3	0.000.0	0.00-0.1	0.08-0.0	0.10+0.1	0.02-0.1	0.11
Debt-to-Equity	-1.76+0.0	-1.77-0.8	-1.000.0	-1.00-1.0	-0.01-0.2	0.230.0	0.23+0.0	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Canaquest Medica CANQF

$296K

Hempamericana HMPQ

$292K

Indoor Harvest INQD

$321K

Arev Life Sciences Global Corp AREVF

$318K

Lowell Farms LOWLF

$309K

Frequently Asked Questions

Is Alterola Biotech profitable?

No, Alterola Biotech (ABTI) reported a net income of -$2.4M in fiscal year 2024.

What is Alterola Biotech's operating cash flow?

Alterola Biotech (ABTI) generated -$1.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Alterola Biotech's total assets?

Alterola Biotech (ABTI) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Alterola Biotech spend on research and development?

Alterola Biotech (ABTI) invested $29K in research and development during fiscal year 2024.

How many shares does Alterola Biotech have outstanding?

Alterola Biotech (ABTI) had 1.38B shares outstanding as of fiscal year 2024.

What is Alterola Biotech's current ratio?

Alterola Biotech (ABTI) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Alterola Biotech's debt-to-equity ratio?

Alterola Biotech (ABTI) had a debt-to-equity ratio of -1.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alterola Biotech's return on assets (ROA)?

Alterola Biotech (ABTI) had a return on assets of -64820.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Alterola Biotech's cash runway?

Based on fiscal year 2024 data, Alterola Biotech (ABTI) had $3K in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Alterola Biotech's debt-to-equity ratio negative or unusual?

Alterola Biotech (ABTI) has negative shareholder equity of -$1.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Alterola Biotech's Piotroski F-Score?

Alterola Biotech (ABTI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alterola Biotech's earnings high quality?

Alterola Biotech (ABTI) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.